Johnson & Johnson (JNJ) operating KPIs
JNJNYSEPharmaceutical PreparationsFiscal year ends January 3
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Oct 21, 2026Score 12/3043% above fair value
$273.20−2.00 (-0.73%)
Close on Oct 30, 2026Market cap $658.38BP/E 31.7Yield 1.88%
Johnson & Johnson rYBREVANT / LAZCLUZE (amivantamab / lazertinib) — U.S. operational growth YoY (%) (%)
Form 8-K EX-99.2 Segment Sales Schedule
Latest, Q3 2026
47.9%
Period ended Sep 30, 2026
Change on a year earlier
-51.8 pts
99.7% in Q3 2025
History
6 quarters
Since Q1 2025
Sources
6
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | RYBREVANT / LAZCLUZE (amivantamab / lazertinib) — U.S. operational growth YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| Q3 2026 | Sep 30, 2026 | 47.9% | -51.8 pts | Form 8-K (a2026q3exhibit991.htm, filed 2026-10-13) ↗ |
| Q2 2026 | Jun 28, 2026 | 36.8% | – | Form 8-K (a2026q2exhibit991.htm, filed 2026-07-15) ↗ |
| Q1 2026 | Mar 29, 2026 | 55.1% | -12.9 pts | Form 8-K (a2026q1exhibit991.htm, filed 2026-04-14) ↗ |
| Q4 2025 | Dec 28, 2025 | 45.6% | – | Form 8-K (a2025q4exhibit991.htm, filed 2026-01-21) ↗ |
| Q3 2025 | Sep 28, 2025 | 99.7% | – | Form 8-K (a2025q3exhibit991.htm, filed 2025-10-14) ↗ |
| Q1 2025 | Mar 30, 2025 | 68.0% | – | Form 8-K (a2025q1exhibit991.htm, filed 2025-04-15) ↗ |
Cite this data
StockData. (2026). Johnson & Johnson RYBREVANT / LAZCLUZE (amivantamab / lazertinib) — U.S. operational growth YoY (%) (%), quarterly Q1 2025–Q3 2026 [Data set]. Compiled from Johnson & Johnson SEC filings and investor materials. https://stockdatahq.com/stocks/jnj/kpis/drug_rybrevant_us_ops_yoy
See every metric in the Johnson & Johnson KPI table. Data updated Oct 25, 2026.